{"title":"Advances in Research on Risk Factors for Disease Progression in Advanced Prostate Cancer","authors":"Jialiang Li, Jie Yang, Yunpeng He, Jianhe Liu","doi":"10.56397/crms.2023.09.06","DOIUrl":null,"url":null,"abstract":"Advanced prostate cancer has mostly lost the chance of surgery, and has a low 5-year survival rate and high mortality rate. Therefore, exploring the risk factors for advanced prostate cancer disease progression can help formulate scientific and standardized treatment plans and strategies for advanced prostate cancer disease progression. Intervention measures provide evidence to improve the quality of life and survival rate of patients. Based on the existing research reports at home and abroad, I reviewed the risk factors related to the progression of advanced prostate cancer.","PeriodicalId":72751,"journal":{"name":"Current research in medical sciences","volume":"24 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current research in medical sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.56397/crms.2023.09.06","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Advanced prostate cancer has mostly lost the chance of surgery, and has a low 5-year survival rate and high mortality rate. Therefore, exploring the risk factors for advanced prostate cancer disease progression can help formulate scientific and standardized treatment plans and strategies for advanced prostate cancer disease progression. Intervention measures provide evidence to improve the quality of life and survival rate of patients. Based on the existing research reports at home and abroad, I reviewed the risk factors related to the progression of advanced prostate cancer.